Wendy Stock, Geoffrey Uy named leukemia committee co-chairs of Alliance for Clinical Trials in Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Wendy Stock and Geoffrey Uy were named co-chairs of the Leukemia Committee of the Alliance for Clinical Trials in Oncology. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.
Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels. 
As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login